Cargando…

Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers

BACKGROUND: Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools. The objective of this study is to develop a new method for the differential diagnosis and identification of new...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jahn, Holger, Wittke, Stefan, Zürbig, Petra, Raedler, Thomas J., Arlt, Sönke, Kellmann, Markus, Mullen, William, Eichenlaub, Martin, Mischak, Harald, Wiedemann, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202544/ https://www.ncbi.nlm.nih.gov/pubmed/22046305 http://dx.doi.org/10.1371/journal.pone.0026540

Ejemplares similares

Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease
por: Dakterzada, Farida, et al.
Publicado: (2023)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes
por: Magalhães, Pedro, et al.
Publicado: (2020)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
por: Denk, Johannes, et al.
Publicado: (2015)

Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome
por: He, Tianlin, et al.
Publicado: (2020)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum
por: Wang, Jun, et al.
Publicado: (2020)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
por: Andersen, Sten, et al.
Publicado: (2010)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2022)

Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease
por: Nkuipou-Kenfack, Esther, et al.
Publicado: (2014)

Non-Alzheimer's disease—related memory impairment and dementia
por: Arlt, Sönke
Publicado: (2013)

Publisher Correction: Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2018)

Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2018)

Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer Disease: Protocol for a Cross-Sectional Study
por: Tarawneh, Rawan
Publicado: (2019)

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
por: Kivisäkk, Pia, et al.
Publicado: (2022)

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
por: Silverberg, Gerald, et al.
Publicado: (2006)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease
por: Barichello, Tatiana, et al.
Publicado: (2019)

Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lim, Bryant, et al.
Publicado: (2019)

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
por: Do, Khanh V., et al.
Publicado: (2022)

Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder
por: Al Shweiki, MHD Rami, et al.
Publicado: (2020)

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

Early onset of treatment effects with oral risperidone
por: Raedler, Thomas J, et al.
Publicado: (2007)

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease
por: Kramberger, Milica Gregoric, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cptliap6g8groc59u40l4nafl3